NP47827 Multiple Sclerosis Medicines
The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine
Buyer
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
Value
£30,403,887
Published
26 Oct 2026
Closes
22 Jan 2027
Procurement details
Source
Find a Tender
Region
Scotland
Procurement method
Not provided
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 Glatiramer acetate, Interferon beta-1a and Natalizumab
Value not provided
Supply of Glatiramer acetate, Interferon beta-1a and Natalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.
Delivery: Scotland
Lot 3 Cladribine tablets
Value not provided
Supply of cladribine tablets to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.
Delivery: Scotland
Lot 2 Fingolimod, Teriflunomide and Dimethyl Fumarate
Value not provided
Supply of Fingolimod, Teriflunomide and Dimethyl Fumarate to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.
Delivery: Scotland
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.